Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858471 | 1.00 | KMT2A (0.46) | KMT2AMEN1P2RY1POLBPTGDR2 | |
| SCHEMBL3854919 | 1.00 | KMT2A (0.46) | KMT2AMEN1P2RY1POLBPTGDR2 | |
| SCHEMBL3853980 | 0.88 | MGLL (0.41) | KMT2AMEN1P2RY1POLBGPR3 | |
| SCHEMBL3854609 | 0.88 | MGLL (0.41) | KMT2AMEN1P2RY1POLBGPR3 | |
| SCHEMBL3854470 | 0.88 | MGLL (0.41) | KMT2AMEN1P2RY1POLBGPR3 | |
| SCHEMBL3859881 | 0.87 | BCHE (0.50) | KMT2AMEN1P2RY1PTGDR2HCRTR2 | |
| SCHEMBL3860354 | 0.86 | KMT2A (0.46) | KMT2AMEN1POLBGPR3 | |
| SCHEMBL3855998 | 0.86 | KMT2A (0.46) | KMT2AMEN1POLBGPR3 | |
| SCHEMBL3855449 | 0.86 | KMT2A (0.46) | KMT2AMEN1POLBGPR3 | |
| SCHEMBL3862745 | 0.85 | PDK1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585871-B2 | 4-{[(6R)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 3-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 4-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; cytokine expression | WYETH (US) | 2009-09-08 | — | — | US | claimed |
| US-20060058337-A1 | Phenanthridine carbonyl phenols | WYETH (US) | 2006-03-16 | — | — | US | claimed |
| US-7585871-B2 | 4-{[(6R)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 3-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 4-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; cytokine expression | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1784391-A1 | PHENANTHRIDINE CARBONYL PHENOLS AS CYTOKINE EXPRESSION MODULATORS | Wyeth (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060058337-A1 | Phenanthridine carbonyl phenols | WYETH (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006028875-A1 | PHENANTHRIDINE CARBONYL PHENOLS AS CYTOKINE MODULATORS | WYETH (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058337-A1 | Phenanthridine carbonyl phenols | MT-CO2, PAH, CBR3 | KMT2A 1282/4885MEN1 3644/4885P2RY1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.